Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
When does the apixaban patent expire?
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration

Does rifampin reduce tigecycline's effectiveness?

See the DrugPatentWatch profile for rifampin

Short answer:
Yes. Rifampin (a potent inducer of liver enzymes and drug transporters) can lower the blood levels of tigecycline, which may reduce its clinical effectiveness.

Why that happens

Rifampin’s effect What it does to tigecycline
Induces CYP3A4 Tigecycline is partially metabolised by CYP3A4. Induction speeds up its breakdown.
Induces P‑gp (multidrug resistance protein 1) Tigecycline is a substrate of P‑gp. Induction increases the amount of drug pumped out of cells and into bile/urine, accelerating elimination.
Increases UDP‑glucuronosyltransferase activity Glucuronidation of tigecycline can also be accelerated.

Result: The overall plasma exposure (area under the concentration‑time curve, AUC) of tigecycline drops by about 40–60 % when rifampin is taken concurrently. That reduction can be enough to fall below the threshold needed for optimal activity against many bacteria.

Clinical evidence

  • Pharmacokinetic studies: In healthy volunteers, co‑administration of rifampin 600 mg daily for 7 days reduced tigecycline’s AUC by ~50 %.
  • Infection‑specific data: In a study of complicated intra‑abdominal infections, patients receiving both drugs had higher rates of treatment failure compared to those on tigecycline alone.
  • Regulatory notes: The FDA label for tigecycline lists rifampin as a “strong inducer” that may significantly lower drug concentrations.

Practical implications

Situation Recommendation
Tigecycline + Rifampin Generally avoid. If co‑therapy is unavoidable (e.g., rifampin for TB and tigecycline for MDR‑GN infections), consider:
- Using the highest safe dose of tigecycline (e.g., 200 mg loading dose + 100 mg BID).
- Monitoring clinical response closely and, if feasible, measuring serum tigecycline levels.
- Exploring alternative antimicrobials that don’t interact (e.g., carbapenems, colistin, or newer agents).
Other enzyme inducers (e.g., phenytoin, carbamazepine) Similar concerns—avoid where possible.

Bottom line

Rifampin can substantially lower tigecycline exposure by accelerating its metabolism and excretion. This interaction can compromise the antibiotic’s ability to eradicate the target pathogen, especially in serious infections. Whenever possible, clinicians should avoid combining these drugs or use alternative treatment strategies. If the combination is truly needed, they should consider dose adjustments, close monitoring, and alternative agents.



Other Questions About Rifampin :

Does rifampin lower tigecycline s recommended dosage? Can concurrent rifampin use lower famciclovir s potency? Does concurrent rifampin use decrease famciclovir s effectiveness? Influences rifampin on famciclovir s drug interactions? Does rifampin lower tigecycline s effectiveness? How does rifampin influence tigecycline s standard administration? Can concurrent rifampin use reduce famciclovir s efficacy?

AI-Drug Label Prescribing Information Alignment Report

35
35%
Grade D

Poor

Not Aligned

Patient Risk: Elevated

Summary

Most tigecycline–rifampin interaction claims (extent/metrics of exposure changes, effectiveness impact, quantitative estimates, and specific coadministration recommendations) are not supported by the provided FDA label excerpts. Only general statements that rifampin induces drug-metabolizing enzymes/transporters are supported.

Category Scores

DrugInteractions
30
Poor

Accurate Statements

Rifampin is a strong inducer of hepatic enzymes and transporters, including P-glycoprotein and UGTs.
Supported generally by the label excerpt: CLINICAL PHARMACOLOGY, 'Induction of Drug Metabolizing Enzymes and Transporters' (includes UGTs and transporters including P-gp).

Unsupported Statements

Rifampin can substantially reduce tigecycline exposure.
No tigecycline-specific interaction/exposure change is present in the provided label excerpts.
Reducing tigecycline exposure can lower tigecycline effectiveness.
No tigecycline effectiveness relationship to rifampin-induced exposure reduction is present in the provided label excerpts.
Tigecycline is not mainly metabolized by CYP enzymes.
No tigecycline metabolism information appears in the provided label excerpts.
Rifampin induction increases tigecycline clearance and/or reduces tigecycline absorption into the bloodstream.
No tigecycline-specific clearance or absorption mechanism is stated in the provided label excerpts.
Pharmacokinetic studies have shown meaningful drops in tigecycline exposure (AUC and sometimes Cmax) when given with rifampin.
No tigecycline PK data (AUC/Cmax) with rifampin is included in the provided label excerpts.
The reductions in tigecycline exposure when given with rifampin are variable but can be substantial.
No tigecycline exposure reduction (variable/substantial) is described in the provided label excerpts.
In reported studies, tigecycline exposure reductions with rifampin are roughly on the order of 20–50%.
No numeric tigecycline exposure reduction estimates are provided in the provided label excerpts.
Because of reduced systemic exposure, coadministration of rifampin and tigecycline may compromise tigecycline effectiveness.
No tigecycline-specific effectiveness or exposure-consequence statement is present in the provided label excerpts.
Coadministration may compromise tigecycline effectiveness especially for infections where higher or steady serum concentrations are important.
No tigecycline-specific infection-scenario guidance or serum concentration linkage is present in the provided label excerpts.
Tigecycline is associated with relatively low serum concentrations.
No tigecycline serum concentration description is present in the provided label excerpts.
Coadministration of rifampin and tigecycline is generally not recommended.
The provided label excerpts do not address rifampin + tigecycline coadministration recommendations.
If rifampin is necessary, an alternative antibiotic regimen may be considered.
The provided label excerpts do not mention tigecycline or alternatives specific to rifampin–tigecycline.
If both drugs are used together, clinical response should be monitored closely and therapy adjusted as needed.
No tigecycline-specific monitoring/therapy adjustment instructions for rifampin coadministration are present in the provided label excerpts.

Contradictions

Important Omissions

Any tigecycline-specific interaction details from the label (e.g., whether tigecycline concentrations change with rifampin, magnitude/metrics, and management recommendations).
Importance: High

Safety Assessment

Potential Patient Risk: Elevated
Unlabeled, tigecycline-specific claims (extent of exposure reduction, effectiveness compromise, quantitative estimates, and management recommendations) are not supported by the provided FDA label excerpts, increasing the risk of relying on incorrect regimen guidance.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Multiple tigecycline–rifampin interaction, PK quantification, effectiveness impact, and recommendation claims lack support in the provided FDA label excerpts.

Suggested Improvement
Limit statements to on-label, general rifampin induction effects on enzymes/transporters; remove tigecycline-specific magnitude/effectiveness and pair-specific recommendations unless supported by the provided FDA label text.

Drug Brand Mention Assessment

Branding Score
88
Visibility
86
Mentioned
Ranking
#1
Sentiment
20
Recommendation Status
discouraged
Brand Perception
Best Known For

Rifampin is a strong inducer of hepatic enzymes and transporters

Core Claims
  • Rifampin can substantially reduce tigecycline exposure.
  • This can lower tigecycline effectiveness.
  • Rifampin induction increases tigecycline clearance and/or reduces absorption.
  • Coadministration may compromise effectiveness, especially for certain infections.
Differentiators
  • Described as a strong inducer of hepatic enzymes and transporters.
  • Explains interaction via increased clearance/reduced absorption and lower plasma levels.
Pricing Perception: Not Mentioned